Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

被引：0
|
作者：
Ren, Yuhong [1 ]
Zhuang, Jingli [2 ]
Yuan, Ling [2 ]
Ji, Lili [1 ]
Ke, Yang [1 ]
Liu, Peng [3 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Hematol, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [32] Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
    Kambhampati, Swetha
    Saumoy, Monica
    Pak, Stacy
    Budde, L. Elizabeth
    Mei, Matthew Genyeh
    Popplewell, Leslie
    Wen, Yi-Ping
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Herrera, Alex Francisco
    Thiruvengadam, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
    Younes, Anas
    Burke, John M.
    Cheson, Bruce D.
    Diefenbach, Catherine S.
    Ferrari, Silvia
    Hahn, Uwe H.
    Hawkes, Eliza A.
    Khan, Cyrus
    Lossos, Izidore S.
    Musuraca, Gerardo
    Tani, Monica
    Vitolo, Umberto
    Yuen, Sam
    Raval, Aparna
    Shivhare, Mahesh
    Nielsen, Tina G.
    Sellam, Gila
    Sharman, Jeff P.
    BLOOD ADVANCES, 2023, 7 (08) : 1488 - 1495
  • [34] Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions
    Major, Ajay
    Cliff, Edward R. Scheffer
    Ermann, Daniel A.
    Durani, Urshila
    Russler-Germain, David A.
    EJHAEM, 2022, 3 (03): : 930 - 935
  • [35] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [36] Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Eslami, Mohammadreza
    Mehrabi, Mahdi
    Payandeh, Mehrdad
    Saba, Fakhredin
    PLOS ONE, 2024, 19 (08):
  • [37] Rituximab and CHOP for elderly patients with diffuse large B-cell lymphoma
    Carol S. Portlock
    Current Oncology Reports, 2003, 5 (5) : 357 - 357
  • [38] Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
    Anderson, Kara
    Shehata, Mena
    Singh, Davinder
    Al-Ourani, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [39] Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma
    Corcoran, Sean R.
    Choi, Jaewoo
    Fenner, Rachel E.
    Yu, Xin
    Scheich, Sebastian
    Hsiao, Tony
    Schevchenko, Galina
    Morris, Vivian M.
    Phelan, James D.
    Papachristou, Evangelia K.
    Kishore, Kamal
    D'Santos, Clive S.
    Ji, Yanlong
    Pittaluga, Stefania
    Wright, George
    Urlaub, Henning
    Pan, Kuan-Ting
    Oellerich, Thomas
    Muppidi, Jagan R.
    Hodson, Daniel James
    Staudt, Louis M.
    BLOOD, 2023, 142
  • [40] Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
    Kambhampati, Swetha
    Shumilov, Evgenii
    Saumoy, Monica
    Herrera, Alex F.
    Tilly, Herve
    Lenz, Georg
    Thiruvengadam, Nikhil R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (04) : 771 - 775
12345